insmed inc. - INSM
INSM
Close Chg Chg %
126.29 -1.40 -1.11%
Pre-Market
124.89
-1.40 (1.11%)
Volume: 1.61M
Last Updated:
Sep 8, 2026, 4:00 PM EDT
Company Overview: insmed inc. - INSM
INSM Key Data
| Open $124.79 | Day Range 121.38 - 127.42 |
| 52 Week Range 90.39 - 212.75 | Market Cap $27.58B |
| Shares Outstanding 218.38M | Public Float 215.10M |
| Beta 0.82 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$4.11 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.89M |
INSM Performance
| 1 Week | -1.11% | ||
| 1 Month | -4.74% | ||
| 3 Months | 27.63% | ||
| 1 Year | -14.42% | ||
| 5 Years | 360.00% |
INSM Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
25
Full Ratings ➔
About insmed inc. - INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
INSM At a Glance
Insmed, Inc.
700 US Highway 202/206
Bridgewater, New Jersey 08807-3365
| Phone | 1-908-977-9900 | Revenue | 606.42M | |
| Industry | Pharmaceuticals: Major | Net Income | -1,276,775,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 66.734% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,664 | |
| View SEC Filings |
INSM Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 57.116 |
| Price to Book Ratio | 50.46 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -34.715 |
| Enterprise Value to Sales | 56.004 |
| Total Debt to Enterprise Value | 0.022 |
INSM Efficiency
| Revenue/Employee | 364,436.899 |
| Income Per Employee | -767,292.668 |
| Receivables Turnover | 4.305 |
| Total Asset Turnover | 0.283 |
INSM Liquidity
| Current Ratio | 3.827 |
| Quick Ratio | 3.545 |
| Cash Ratio | 3.05 |
INSM Profitability
| Gross Margin | 78.738 |
| Operating Margin | -164.04 |
| Pretax Margin | -209.713 |
| Net Margin | -210.542 |
| Return on Assets | -59.526 |
| Return on Equity | -249.284 |
| Return on Total Capital | -85.405 |
| Return on Invested Capital | -83.485 |
INSM Capital Structure
| Total Debt to Total Equity | 102.302 |
| Total Debt to Total Capital | 50.569 |
| Total Debt to Total Assets | 33.383 |
| Long-Term Debt to Equity | 99.695 |
| Long-Term Debt to Total Capital | 49.28 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Insmed Inc. - INSM
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 245.36M | 305.21M | 363.71M | 606.42M | |
Sales Growth
| +30.19% | +24.39% | +19.17% | +66.73% | |
Cost of Goods Sold (COGS) incl D&A
| 60.18M | 70.63M | 90.79M | 128.94M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 24.27M | 10.58M | 11.01M | 16.45M | |
Depreciation
| 19.21M | 5.53M | 5.96M | 10.45M | |
Amortization of Intangibles
| 5.05M | 5.05M | 5.05M | 6.00M | |
COGS Growth
| +22.31% | +17.36% | +28.56% | +42.01% | |
Gross Income
| 185.18M | 234.58M | 272.91M | 477.48M | |
Gross Income Growth
| +32.98% | +26.68% | +16.34% | +74.96% | |
Gross Profit Margin
| +75.47% | +76.86% | +75.04% | +78.74% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 663.30M | 915.51M | 1.06B | 1.47B | |
Research & Development
| 397.52M | 571.01M | 598.37M | 771.09M | |
Other SG&A
| 265.78M | 344.50M | 461.12M | 701.17M | |
SGA Growth
| +30.98% | +38.02% | +15.73% | +38.96% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| (19.28M) | 28.38M | 91.92M | 251.99M | |
EBIT after Unusual Expense
| (458.85M) | (709.31M) | (878.49M) | (1.25B) | |
Non Operating Income/Expense
| 5.14M | 43.99M | 53.34M | 58.81M | |
Non-Operating Interest Income
| 11.08M | 42.13M | 53.31M | 60.66M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 26.45M | 81.69M | 84.91M | 83.80M | |
Interest Expense Growth
| -34.66% | +208.91% | +3.94% | -1.32% | |
Gross Interest Expense
| 26.45M | 81.69M | 84.91M | 83.80M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (480.15M) | (747.01M) | (910.07M) | (1.27B) | |
Pretax Income Growth
| -10.02% | -55.58% | -21.83% | -39.74% | |
Pretax Margin
| -195.69% | -244.76% | -250.22% | -209.71% | |
Income Tax
| 1.38M | 2.56M | 3.71M | 5.03M | |
Income Tax - Current - Domestic
| 269.00K | 378.00K | 356.00K | 577.00K | |
Income Tax - Current - Foreign
| 1.34M | 2.23M | 3.38M | 4.48M | |
Income Tax - Deferred - Domestic
| (231.00K) | (54.00K) | (29.00K) | (27.00K) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (481.53M) | (749.57M) | (913.77M) | (1.28B) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (481.53M) | (749.57M) | (913.77M) | (1.28B) | |
Net Income Growth
| -10.79% | -55.66% | -21.91% | -39.73% | |
Net Margin Growth
| -196.26% | -245.59% | -251.24% | -210.54% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (481.53M) | (749.57M) | (913.77M) | (1.28B) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (481.53M) | (749.57M) | (913.77M) | (1.28B) | |
EPS (Basic)
| -3.9138 | -5.3375 | -5.5703 | -6.4155 | |
EPS (Basic) Growth
| -0.95% | -36.38% | -4.36% | -15.17% | |
Basic Shares Outstanding
| 123.03M | 140.43M | 164.04M | 199.01M | |
EPS (Diluted)
| -3.9138 | -5.3375 | -5.5703 | -6.4155 | |
EPS (Diluted) Growth
| -0.95% | -36.38% | -4.36% | -15.17% | |
Diluted Shares Outstanding
| 123.03M | 140.43M | 164.04M | 199.01M | |
EBITDA
| (453.86M) | (670.35M) | (775.56M) | (978.33M) | |
EBITDA Growth
| -33.76% | -47.70% | -15.69% | -26.14% | |
EBITDA Margin
| -184.98% | -219.64% | -213.24% | -161.33% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 200.182 | |
| Number of Ratings | 25 | Current Quarters Estimate | -0.389 | |
| FY Report Date | 09 / 2026 | Current Year's Estimate | -1.599 | |
| Last Quarter’s Earnings | -0.06 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -6.42 | Next Fiscal Year Estimate | 0.961 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 21 | 21 | 23 | 23 |
| Mean Estimate | -0.39 | -0.34 | -1.60 | 0.96 |
| High Estimates | 0.04 | 0.35 | -0.43 | 3.26 |
| Low Estimate | -0.90 | -1.12 | -2.65 | -0.08 |
| Coefficient of Variance | -51.21 | -95.98 | -30.45 | 85.45 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 22 | 22 | 21 |
| OVERWEIGHT | 3 | 3 | 3 |
| HOLD | 0 | 0 | 0 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Insmed Inc. - INSM
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Insmed Inc. - INSM
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 307,444 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $30.46 per share | 9,364,744.24 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 311,884 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.16 per share | 5,351,929.44 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 311,451 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $134.18 per share | 41,790,495.18 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 310,852 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $135.18 per share | 42,020,973.36 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 305,534 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $137.01 per share | 41,861,213.34 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 302,813 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $137.86 per share | 41,745,800.18 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 301,566 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $139.09 per share | 41,944,814.94 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 301,185 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $139.6 per share | 42,045,426.00 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 31,296 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 7, 2026 | William H. Lewis Chair and CEO; Director | 22,200 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 6, 2026 | Melvin Sharoky Director | 242,776 | Bona fide gift | 0.00 |
| Mar 6, 2026 | William H. Lewis Chair and CEO; Director | 39,960 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2026 | Michael A. Smith Chief Legal Officer | 76,645 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $17.07 per share | 1,308,330.15 |
| Feb 26, 2026 | Michael A. Smith Chief Legal Officer | 71,793 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $153.93 per share | 11,051,096.49 |
| Feb 26, 2026 | Michael A. Smith Chief Legal Officer | 67,642 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $155.06 per share | 10,488,568.52 |
| Feb 26, 2026 | Michael A. Smith Chief Legal Officer | 14,282 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 26, 2026 | Michael A. Smith Chief Legal Officer | 51,871 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $156.53 per share | 8,119,367.63 |
| Feb 26, 2026 | David Richard Brennan Director | 60,933 | Bona fide gift | 0.00 |
| Jan 14, 2026 | Martina Flammer Chief Medical Officer | 84,907 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $186.19 per share | 15,808,834.33 |
| Jan 14, 2026 | William H. Lewis Chair and CEO; Director | 57,720 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |